



Project Summary Information

Date of Document Preparation: July 1, 2022	
Project Name	COVID-19 Vaccine Project under the COVID-19 Crisis Recovery Facility
Project Number	P000640
AIIB member	Republic of Türkiye
Sector/Subsector	Public Health / N/A
Status of Financing	Approved
Project Description	<p>The proposed loan will be financed under the AIIB's COVID-19 Crisis Recovery Facility in the amount of EUR225.347 million. AIIB will co-finance the World Bank (WB)'s Additional Financing (the Project) of the Türkiye Emergency COVID-19 Health Project (USD100 million, approved in April 2020).</p> <p>The Project comprises the vaccine procurement and vaccine awareness and communication activities. AIIB will finance the same activities as the WB on a pro rata basis. The implementation period is expected from July 2022 to December 2023.</p>
Objective	To enable affordable and equitable access to COVID-19 vaccines ¹ in Türkiye and to help ensure effective vaccine deployment by strengthening the vaccination system.
Expected Results	<p>The proposed Project results will include:</p> <p>(a) Vaccination coverage of about 37.2% of total population against COVID-19; and</p> <p>(b) Effective public communication and awareness improvement with a focus on vulnerable groups.</p>
Environmental and Social Category	WB Category: Substantial Risk (equivalent to Category B if AIIB's ESP were applicable)
Environmental and Social Information	The loan is co-financed with the WB as lead co-financier, and therefore the project's environmental and social (ES) risks and impacts have been assessed in accordance with the WB's Environmental and Social Framework (ESF) and the ES Standards under ESF. To ensure a harmonized approach to addressing the ES risks and impacts of the project, and as

¹ As of April 16, 2021, the World Bank will accept as the threshold for eligibility of IBRD/IDA resources in COVID-19 vaccine acquisition and/or deployment under all World Bank-financed projects: (i) vaccines that have received regular or emergency licensure or authorization from at least one of the Stringent Regulatory Authorities identified by the World Health Organization (WHO) for vaccines procured and/or supplied under the COVAX Facility, as may be amended from time to time by WHO; or (ii) vaccines that have received WHO Prequalification or WHO Emergency Use Listing.

permitted under AIIB's Environmental and Social Policy (ESP), the WB ESF will apply to the project in lieu of AIIB's ESP. AIIB has reviewed the WB's ESF and is satisfied that: (a) it is consistent with AIIB's Articles of Agreement and materially consistent with the provisions of AIIB's ESP, including the Environmental and Social Exclusion List and the relevant ES Standards; and (b) the monitoring procedures in place are appropriate for the project.

The WB has categorized the ES risks of the project as "Substantial" (which is equivalent to Category B if AIIB's ESP were applicable). The Ministry of Health (MoH) has prepared the Environmental and Social Management Framework (ESMF) and Stakeholder Engagement Plan (SEP) for the parent Project and has updated them for the proposed Project. The updated ESMF covers all activities, as well as procedures for the screening and the identification of environmental and social risks and mitigation measures to be implemented in relation to the COVID-19 vaccine procurement and deployment, which include ensuring effective on-site medical waste management, storage, transportation, and disposal schemes. Mitigation measures will be based on the World Health Organization's COVID-19 response technical guidance on limiting viral contagion in healthcare facilities, the World Bank Group Environmental, Health and Safety Guidelines, respective national regulations and other good international industry practices. The ESMF includes an Infection and Prevention Control Protocol for Healthcare Settings and Waste Management Plan for Hospitals, which describe in detail appropriate waste management practices applicable.

The updated SEP covers identified primary stakeholders for all activities and integrates elements of the Government communication plan to address COVID-19 vaccine hesitancy. The SEP will continue to be a key instrument for community outreach on issues related to social distancing, higher risk demographics, and quarantine measures. Since the Project includes all provinces in Türkiye, existing national grievance mechanisms that are already in use will be integrated to newly established Grievance Redress Mechanism (GRM). The GRM also allows workers to promptly inform management of labor issues, such as a lack of personal protective equipment, unreasonable overtime, stress and any Sexual Exploitation and Abuse/Sexual Harassment related issues in the workplace. This workers' GRM allows for anonymous grievances and has an appeal's process in place. Responsible party for the maintenance and monitoring of the GRM will be MoH through its Project Management and Support Unit.

The ES instruments including the ES Commitment Plan, ESMF (including the Labor Management Procedures) and SEP have been disclosed by the MoH in April, 2022.² The Project implementation will conduct appropriate stakeholder

² <https://pydb.saglik.gov.tr/TR-87459/covid-19-saglikta-acil-durum-projesi-ek-finansman.html>, accessed on June 29, 2022.

	engagement, proper awareness-raising on COVID-19 prevention and control and vaccine access, and timely information dissemination. WB will conduct regular project implementation monitoring and the ES monitoring reports will be shared with AIIB. AIIB will join WB's meetings and missions virtually, and in person when and where possible.			
Cost and Financing Plan	The total Project cost is EUR676 million (USD750 million equivalent).			
	Modality and Sources			Amount (USD million equivalent)
	World Bank*			500.0
	AIIB Sovereign-Backed Financing COVID-19 Crisis Recovery Facility			250.0
	Total			750.0
	*WB's parent loan is in the amount of USD100 million.			
Borrower	Republic of Türkiye			
Implementing Entity	MoH			
Estimated date of loan closing	December, 2023			
Contact Points:	AIIB	WB	Borrower	Implementing Entity
Name	Zhaojing Mu	Nadwa Rafeh	Sedef Aydaş	Zahide Şenalp
Title	Senior Operations Management Officer	Senior Health Specialist	Head of Department Ministry of Treasury and Finance	Director Project Management Support Unit Ministry of Health
Email Address	zhaojing.mu@aiib.org	nrafeh@worldbank.org	sedef.aydas@hmb.gov.tr	zahide.senalp@saglik.gov.tr
Date of Concept Decision	April 20, 2022			
Date of Appraisal Decision/Estimated Date of Appraisal Decision	June 1, 2022			
Date of Financing Approval	June 29, 2022			

Independent Accountability Mechanism	<p>As noted above, the WB's ESF will apply to this project instead of AIIB's ESP. The WB's corporate Grievance Redress Service and its Independent Accountability Mechanism (IAM) including the Inspection Panel, which review the WB's compliance with its policies and procedures, will handle complaints relating to the WB's compliance with its ESF with respect to the Project. In accordance with AIIB's Policy on the Project-affected People's Mechanism (PPM), submissions made to the PPM regarding such complaints under the Project will not be eligible for consideration by the PPM. Information on WB's corporate Grievance Redress Service is available at http://www.worldbank.org/en/projects-operations/products-and-services/grievance-redress-service. Information on WB's IAM is available at https://www.worldbank.org/en/programs/accountability.</p>
---	---